Article

Glycine Decarboxylase Activity Drives Non-Small Cell Lung Cancer Tumor-Initiating Cells and Tumorigenesis

Stem Cell and Developmental Biology, Genome Institute of Singapore, 60 Biopolis Street, Singapore 138672.
Cell (Impact Factor: 33.12). 01/2012; 148(1-2):259-72. DOI: 10.1016/j.cell.2011.11.050
Source: PubMed

ABSTRACT Identification of the factors critical to the tumor-initiating cell (TIC) state may open new avenues in cancer therapy. Here we show that the metabolic enzyme glycine decarboxylase (GLDC) is critical for TICs in non-small cell lung cancer (NSCLC). TICs from primary NSCLC tumors express high levels of the oncogenic stem cell factor LIN28B and GLDC, which are both required for TIC growth and tumorigenesis. Overexpression of GLDC and other glycine/serine enzymes, but not catalytically inactive GLDC, promotes cellular transformation and tumorigenesis. We found that GLDC induces dramatic changes in glycolysis and glycine/serine metabolism, leading to changes in pyrimidine metabolism to regulate cancer cell proliferation. In the clinic, aberrant activation of GLDC correlates with poorer survival in lung cancer patients, and aberrant GLDC expression is observed in multiple cancer types. This link between glycine metabolism and tumorigenesis may provide novel targets for advancing anticancer therapy.

Download full-text

Full-text

Available from: Moni Soroush, May 19, 2014
3 Followers
 · 
321 Views
  • Source
    • "Acute lymphoid leukemia CD34 + CD19 − [45], CD34 + CD38 − [46] Breast cancer CD44 + CD24 − [5] [47], CD55 + [48], CD61 + [49] Brain cancer CD133 + [6] [50], CD133 + EGFRvIII + [27], SSEA-1 + [51], integrin α6 hi [52] Colon cancer CD133 + [7], EpCAM hi CD44 + [53] [54], CD66c bright [55] Prostate cancer CD44 + α2β1 hi CD133 + [56] [57] Pancreatic cancer CD44 + CD24 + ESA + [8], CD133 + CXCR4 + [58], FoxM1 hi [59] Head and neck cancer CD44 + [60] [61] Ovarian cancer CD44 + CD117 + [9], CD133 + [62] Lung cancer CD133 + [10], CD44 + [63], CD166 + [18] Liver cancer CD133 + [64],CD90 + [65] Gastric cancer CD44 + [66] [67] Melanoma ABCB5 + [68], CD133 + [69] perivascular niches also contributed to CSC multidrug resistance phenotype [35]. For example, CSCs increasing in hypoxic niche could decrease their sensitivity to antiangiogenic agents in breast cancer [36]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Accumulating evidence suggests that cancer stem cells (CSCs) are heterogeneous populations and their phenotypes are unstable. A number of intrinsic and extrinsic mechanisms contribute to CSC phenotypic variation. The existence of various CSC subpopulations which would lead to a rapid relapse after primary treatments might pose a problem for CSC targeted therapeutics. In order to develop more effective approaches to cancer therapeutics, more CSC-related surface markers or targeting molecules, as well as some novel targeting strategies should be explored. This review summarized the origin and performance of heterogeneity in CSCs and discussed their therapeutic implications. Copyright © 2014. Published by Elsevier Ireland Ltd.
    Cancer Letters 11/2014; 357(1). DOI:10.1016/j.canlet.2014.11.040 · 5.62 Impact Factor
  • Source
    • "Serine can be incorporated into proteins or shuttled into the glycine synthesis pathway and further towards pyrimidine metabolism. Glycine decarboxylase (GLDC), an enzyme upregulated in several cancers, can drive the flux from serine to pyrimidine synthesis [41], but recent evidence indicates that serine, not glycine, supports cancer cell proliferation [42]. Similarly, the PPP and the hexosamine biosynthesis pathway (HBP) use glucose for anabolism and protein glycosylation (see below) [40,43-46]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The stromal vasculature in tumors is a vital conduit of nutrients and oxygen for cancer cells. To date, the vast majority of studies have focused on unraveling the genetic basis of vessel sprouting (also termed angiogenesis). In contrast to the widely studied changes in cancer cell metabolism, insight in the metabolic regulation of angiogenesis is only just emerging. These studies show that metabolic pathways in endothelial cells (ECs) importantly regulate angiogenesis in conjunction with genetic signals. In this review, we will highlight these emerging insights in EC metabolism and discuss them in perspective of cancer cell metabolism. While it is generally assumed that cancer cells have unique metabolic adaptations, not shared by healthy non-transformed cells, we will discuss parallels and highlight differences between endothelial and cancer cell metabolism and consider possible novel therapeutic opportunities arising from targeting both cancer and endothelial cells.
    09/2014; 2(1):19. DOI:10.1186/2049-3002-2-19
  • Source
    • "Relatively few studies have examined the metabolic underpinnings of the cellular programs that increase cancer cell aggressiveness (Nomura et al., 2010; Ulanovskaya et al., 2013; Zhang et al., 2012). One such program is the epithelial-mesenchymal transition (EMT) (reviewed in Nieto and Cano, 2012) that operates in carcinoma cells and is thought to confer stem-like properties, such as enhanced survival, self-renewal, and anchorage-independent growth, all of which contribute to increased aggressiveness in vivo (Scheel and Weinberg, 2011). "
    [Show abstract] [Hide abstract]
    ABSTRACT: It is increasingly appreciated that oncogenic transformation alters cellular metabolism to facilitate cell proliferation, but less is known about the metabolic changes that promote cancer cell aggressiveness. Here, we analyzed metabolic gene expression in cancer cell lines and found that a set of high-grade carcinoma lines expressing mesenchymal markers share a unique 44 gene signature, designated the "mesenchymal metabolic signature" (MMS). A FACS-based shRNA screen identified several MMS genes as essential for the epithelial-mesenchymal transition (EMT), but not for cell proliferation. Dihydropyrimidine dehydrogenase (DPYD), a pyrimidine-degrading enzyme, was highly expressed upon EMT induction and was necessary for cells to acquire mesenchymal characteristics in vitro and for tumorigenic cells to extravasate into the mouse lung. This role of DPYD was mediated through its catalytic activity and enzymatic products, the dihydropyrimidines. Thus, we identify metabolic processes essential for the EMT, a program associated with the acquisition of metastatic and aggressive cancer cell traits.
    Cell 08/2014; 158(5):1094-109. DOI:10.1016/j.cell.2014.07.032 · 33.12 Impact Factor
Show more